Gain Therapeutics
Bethesda
About Gain Therapeutics
Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct Enzyme Therapy to identify a new generation of uncomplicated adjuvants, enabling clients to help patients stabilize misfolding mutations and restore protein's enzymatic activity. It targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Established in 2017 and is headquartered in Bethesda, MD, USA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $31.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:GANX
- Website: gaintherapeutics.com
- Phone: 301-500-1556
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/gain-therapeutics-60396 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.